Don't miss this work from Duke, presented by MD/PhD student Aditya Mohan, at 2:24: Intracranial IL12 Secreting CAR-T Cells Obviate the Need for Lymphodepletion and Combat Heterogeneity via Microglial Interactions @TheMohanAditya@APatelBrainSurg#DukeAtAANS@DukeMedSchool
We congratulate AACR Past President and #AACRFellows@DrLizJaffee of @hopkinskimmel on being recognized with the 2023 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research. Learn more: https://t.co/xxZXmhUcPY
Congratulations to Lustgarten's Chief Medical Advisor @DrLizJaffee on the 2022 @AACI_Cancer Distinguished Scientist Award for her groundbreaking research in treating pancreatic cancer with immunotherapy. @hopkinskimmel#AACI2022
Phenomenal paper just published in Science persuasively demonstrating that EBV causes most if not all multiple sclerosis.
Phenomenal epidemiological design and technical achievement. 👏
https://t.co/LcNFvKHiUp
Honored to work with such a great team. A modest prolongation of PFS here but hopefully the basis of more effective combinations (follow on cobi/atezo/anti-cd27 in CCA has opened, more to come!) @curecc
New from @MKhasraw, @JohnHSampson, and colleagues in @jitcancer: A new approach to bypassing the blood-brain barrier involves the use of a fusion protein that can be delivered systemically—bispecific T-cell engagers.
https://t.co/LdLM71qn6t
I never expected to enjoy my labor and delivery rotation as much as I did. Two weeks ago I had never seen anything related to childbirth but now I can say I was part of the team that brought 8 beautiful babies into the world. 🤯
Excited to share our newest work on effects of MEK inhibition on the TME, published today in CIR:
https://t.co/EWz7hMKloi
👇Summary & rationale for upcoming study of cobimetinib + atezolizumab + T cell agonist trial in #cholangiocarcinoma
Delighted to share:
JCI - Systemic inhibition of PTPN22 augments anticancer immunity https://t.co/ZnTJZDS2Z5
Building on the work in the autoimmune space, we are excited to show that PTPN22 can be targeted with a small molecule inhibitor to enhance antitumor immunity. 1/4